Analysts Conflicted on These Healthcare Names: Veeva Systems (VEEV) and United Therapeutics (UTHR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Veeva Systems (VEEV – Research Report) and United Therapeutics (UTHR – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Veeva Systems (VEEV)
In a report released yesterday, Bradley Sills from Bank of America Securities maintained a Hold rating on Veeva Systems, with a price target of $304.00. The company’s shares closed last Wednesday at $188.48.
According to TipRanks.com, Sills is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Veeva Systems with a $265.54 average price target, a 42.4% upside from current levels. In a report issued on February 17, Morgan Stanley also upgraded the stock to Hold with a $205.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
United Therapeutics (UTHR)
In a report released today, Ashwani Verma from UBS reiterated a Buy rating on United Therapeutics, with a price target of $705.00. The company’s shares closed last Wednesday at $490.21.
According to TipRanks.com, Verma is a 4-star analyst with an average return of
Currently, the analyst consensus on United Therapeutics is a Moderate Buy with an average price target of $537.00, implying an 8.1% upside from current levels. In a report issued on February 26, Oppenheimer also maintained a Buy rating on the stock with a $600.00 price target.
